Zacks Investment Research upgraded Arbutus Biopharma Corp (NASDAQ:ABUS) to Hold in a report released today.
- Updated: September 17, 2016
Showing a price of $3.94, Arbutus Biopharma Corp (NASDAQ:ABUS) traded 0.26% lower on the day. The last stock price is down 6.73% from the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same period. ABUS has been tracking to a 50-day moving average of $3.87 and two hundred day average of $4.05. Trading volume was was down over the average, with 52,939 shares of ABUS changing hands under the typical 129,352 shares.
Zacks Investment Research has upgraded Arbutus Biopharma Corp(NASDAQ:ABUS) to Hold in a report released 8/18/2016.
A total of 5 equity analysts have issued a ratings update on Arbutus Biopharma Corp. Two firms rate the stock a strong buy, three firms rate the company a buy, 0 firms rate the stock a hold, 0 rate the company to underperform, and lastly 0 analystsrate the company as sell with a consensus target of $13.80
Arbutus Biopharma Corp has a 52 week low of $2.72 and a one-year high of $7.72. Arbutus Biopharma Corp’s total market value is currently $0.0.
General Information About Arbutus Biopharma Corp (NASDAQ:ABUS)
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, and cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.